勘误：丁丙诺啡长效注射剂用于阿片类物质使用障碍的管理：从研发到实施 [勘误]
Erratum: Depot Buprenorphine Injection in the Management of Opioid Use Disorder: From Development to Implementation [Corrigendum].
出版信息
Subst Abuse Rehabil. 2020 Jan 31;11:19-20. doi: 10.2147/SAR.S247083. eCollection 2020.
Abstract
[This corrects the article DOI: 10.2147/SAR.S155843.].
摘要
[本文更正了文章的数字对象标识符：10.2147/SAR.S155843。]
相似文献
1
Erratum: Depot Buprenorphine Injection in the Management of Opioid Use Disorder: From Development to Implementation [Corrigendum].勘误：丁丙诺啡长效注射剂用于阿片类物质使用障碍的管理：从研发到实施 [勘误]
Subst Abuse Rehabil. 2020 Jan 31;11:19-20. doi: 10.2147/SAR.S247083. eCollection 2020.
2
Opioid users' willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder.阿片类药物使用者愿意接受长效丁丙诺啡储库注射治疗阿片类药物使用障碍。
J Subst Abuse Treat. 2019 Sep;104:64-71. doi: 10.1016/j.jsat.2019.06.007. Epub 2019 Jun 9.
3
Open-label trial of an injection depot formulation of buprenorphine in opioid detoxification.丁丙诺啡注射用长效制剂用于阿片类药物脱毒的开放标签试验。
Drug Alcohol Depend. 2004 Jan 7;73(1):11-22. doi: 10.1016/j.drugalcdep.2003.08.006.
4
Evaluation of an injection depot formulation of buprenorphine: placebo comparison.丁丙诺啡注射用长效制剂的评估：与安慰剂对比
Addiction. 2004 Nov;99(11):1439-49. doi: 10.1111/j.1360-0443.2004.00834.x.
5
Depot Buprenorphine Injection In The Management Of Opioid Use Disorder: From Development To Implementation.长效丁丙诺啡注射剂在阿片类物质使用障碍治疗中的应用：从研发到实施
Subst Abuse Rehabil. 2019 Nov 29;10:69-78. doi: 10.2147/SAR.S155843. eCollection 2019.
6
An injection depot formulation of buprenorphine: extended bio-delivery and effects.丁丙诺啡注射长效制剂：延长生物给药及作用
Addiction. 2006 Mar;101(3):420-32. doi: 10.1111/j.1360-0443.2006.01348.x.
7
Clinical applications of buprenorphine depot injection for opioid use disorder.丁丙诺啡长效注射剂在阿片类物质使用障碍中的临床应用
Addiction. 2020 Jan;115(1):190. doi: 10.1111/add.14818. Epub 2019 Nov 12.
8
Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.每月一次丁丙诺啡储库注射治疗阿片类药物使用障碍的疗效和安全性：一项多中心、随机、双盲、安慰剂对照、3 期临床试验。
Lancet. 2019 Feb 23;393(10173):778-790. doi: 10.1016/S0140-6736(18)32259-1. Epub 2019 Feb 18.
9
Depot buprenorphine injections for opioid use disorder: Patient information needs and preferences.阿片类药物使用障碍的丁丙诺啡注射剂：患者信息需求和偏好。
Drug Alcohol Rev. 2019 Jul;38(5):510-518. doi: 10.1111/dar.12939. Epub 2019 May 26.
10
Pharmacokinetics and pharmacodynamics of a buprenorphine subcutaneous depot formulation (CAM2038) for once-weekly dosing in patients with opioid use disorder.一种用于阿片类物质使用障碍患者每周一次给药的丁丙诺啡皮下长效注射剂（CAM2038）的药代动力学和药效学
J Subst Abuse Treat. 2017 Jul;78:22-29. doi: 10.1016/j.jsat.2017.04.008. Epub 2017 Apr 14.
引用本文的文献
1
Provider Perceptions Toward Extended-Release Buprenorphine for Treatment of Opioid Use Disorder.提供者对用于治疗阿片类药物使用障碍的延长释放丁丙诺啡的看法。
J Addict Med. 2024;18(5):540-545. doi: 10.1097/ADM.0000000000001320. Epub 2024 May 31.
2
Increased Treatment Engagement and Adherence: Flexible Management with Prolonged-Release Buprenorphine in Treatment of Opioid Dependence.提高治疗参与度和依从性：长效丁丙诺啡在阿片类药物依赖治疗中的灵活管理。
Case Rep Psychiatry. 2021 Feb 27;2021:6657350. doi: 10.1155/2021/6657350. eCollection 2021.
Zotero 插件